Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
February 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went...
Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
November 22, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
November 10, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 07:15 ET
|
Clearside Biomedical, Inc.
- Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential...
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
November 09, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability,...
Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results
November 08, 2022 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
November 02, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
October 04, 2022 07:05 ET
|
Clearside Biomedical, Inc.
- Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector® - - SCS...
Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 27, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
August 25, 2022 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...